Originally Aired: March 8, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Tuberous sclerosis complex (TSC) is a rare genetic disorder that triggers the development of benign tumors in various parts of the body, often affecting multiple vital organs. With no cure available for this disorder and traditional treatments often requiring invasive surgical techniques, investigators have begun to look toward the success of immunotherapies in treating and managing other diseases.

In this GEN webinar, our distinguished presenter, Dr. I. Caroline Le Poole will discuss identifying benign TSC tumors expressing immunogens that can be targeted by CAR T therapy. Moreover, she will highlight recently published data showing that polyfunctional GD3 CAR T cells created to target the TSC tumor immunogens could substantially reduce tumor burden in a mouse model. We will also learn how single-cell multiplex cytokine profiling via IsoPlexis’ proteomics platform was utilized to uncover rare polyfunctional CAR T cell subsets indicating the functional capacity for improved anti-tumor response.

 

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

 

Isoplexis logo
I. Caroline Le Poole headshot
I. Caroline Le Poole, PhD
Professor of Dermatology and
Microbiology-Immunology
Northwestern University Feinberg School of Medicine